Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of precipitation time of the aluminum salts adsorbed potentially frozen vaccines used in the Polish National Immunization Schedule for their pre-qualification before the administration

  • Paulina Gorska (Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute) ;
  • Maigorzata Giowka (Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute) ;
  • Katarzyna Woznica (Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute) ;
  • Aleksandra A. Zasada (Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute)
  • Received : 2022.03.14
  • Accepted : 2022.05.06
  • Published : 2022.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Vaccines adsorbed on aluminum adjuvants irreversibly lose potency after freezing and their safety is affected. To prevent the administration of such vaccines, the World Health Organization developed the Shake Test designed to determine whether adsorbed vaccines have been frozen or not. However, the Shake Test is difficult and time-consuming when routinely conducted at the place of vaccination. In this study, a modified shake test for prequalification of potentially frozen vaccines was elaborated. Materials and Methods: Vaccines used in the Polish Immunization Schedule were investigated and the analysis includes an assessment of precipitation time and the influence of the container type, amount and type of aluminum compound, and a volume of vaccine dose on the precipitation time. Results: Significant differences between the precipitation time of frozen and non-frozen vaccines routinely used in the Polish Immunization Schedule were observed. The precipitation time of all non-frozen vaccines was above 30 minutes. The longest precipitation time of frozen vaccines was 10 minutes. Conclusion: The finding of the study can be used in practice by the personnel administering vaccines to patients. Step-by-step recommendations for the preparation of the test have been proposed in the article.

Keywords

Acknowledgement

The work was supported by the statuary activity no. 2/EM.2 of the National Institute of the Public Health NIH-National Research Institute, Warsaw, Poland.

References

  1. European Pharmacopoeia Commission, Council of Europe. Vaccines for human use. In: European Pharmacopoeia Commission, Council of Europe, editors. European pharmacopoeia. 9th ed. Strasbourg: Council of Europe; 2017. p. 153.
  2. World Health Organization. Temperature sensitivity of vaccines. Geneva: World Health Organization; 2006.
  3. World Health Organization. Ensuring the quality of vaccines at country level. Geneva: World Health Organization; 2002.
  4. World Health Organization. Guideline for establishing and improving primary and intermediate vaccine stores. Geneva: World Health Organization; 2002.
  5. Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 2007;25:3980-6.
  6. Hanson CM, George AM, Sawadogo A, Schreiber B. Is freezing in the vaccine cold chain an ongoing issue?: a literature review. Vaccine 2017;35:2127-33.
  7. Chen D, Tyagi A, Carpenter J, et al. Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccin 2009;5:26-32.
  8. Kurzatkowski W, Kartoglu U, Staniszewska M, Gorska P, Krause A, Wysocki MJ. Structural damages in adsorbed vaccines affected by freezing. Biologicals 2013;41:71-6.
  9. Kurzatkowski W, Kartoglu U, Gorska P, et al. Physical and chemical changes in Alhydrogel(TM) damaged by freezing. Vaccine 2018;36:6902-10.
  10. Kartoglu U, Ozguler NK, Wolfson LJ, Kurzatkowski W. Validation of the shake test for detecting freeze damage to adsorbed vaccines. Bull World Health Organ 2010;88:624-31.
  11. World Health Organization. Shake and tell [Internet]. New York (NY): Vimeo; 2010 [cited 2018 Jan 6]. Available from: https://vimeo.com/8381355.
  12. World Health Organization. Step by step how to conduct the shake test [Internet]. New York (NY): Vimeo; 2010 [cited 2018 Jan 6]. Available from: https://vimeo.com/54449730.
  13. Kartoglu U, Milstien J. Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev Vaccines 2014;13:843-54.
  14. Kristensen DD, Lorenson T, Bartholomew K, Villadiego S. Can thermostable vaccines help address cold-chain challenges?: results from stakeholder interviews in six low- and middle-income countries. Vaccine 2016;34:899-904.
  15. Goldwood G, Diesburg S. The effect of cool water pack preparation on vaccine vial temperatures in refrigerators. Vaccine 2018;36:128-33.
  16. Lloyd J, Lydon P, Ouhichi R, Zaffran M. Reducing the loss of vaccines from accidental freezing in the cold chain: the experience of continuous temperature monitoring in Tunisia. Vaccine 2015;33:902-7.
  17. Lloyd J, Cheyne J. The origins of the vaccine cold chain and a glimpse of the future. Vaccine 2017;35:2115-20.
  18. Kartoglu U, Nelaj E, Maire D. Improving temperature monitoring in the vaccine cold chain at the periphery: an intervention study using a 30-day electronic refrigerator temperature logger (Fridge-tag). Vaccine 2010;28:4065-72.
  19. Ashok A, Brison M, LeTallec Y. Improving cold chain systems: challenges and solutions. Vaccine 2017;35:2217-23.
  20. Kahn AL, Kristensen D, Rao R. Extending supply chains and improving immunization coverage and equity through controlled temperature chain use of vaccines. Vaccine 2017;35:2214-6.
  21. Diminsky D, Moav N, Gorecki M, Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999;18:3-17.
  22. Maa YF, Zhao L, Payne LG, Chen D. Stabilization of alumadjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 2003;92:319-32.
  23. Clausi AL, Merkley SA, Carpenter JF, Randolph TW. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci 2008;97:2049-61.
  24. Pikal-Cleland KA, Cleland JL, Anchordoquy TJ, Carpenter JF. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J Pharm Sci 2002;91:1969-79.
  25. Braun LJ, Tyagi A, Perkins S, et al. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 2009;27:72-9.
  26. Xue H, Yang B, Kristensen DD, Chen D. A freeze-stable formulation for DTwP and DTaP vaccines. Hum Vaccin Immunother 2014;10:3607-10.
  27. Solanki VA, Jain NK, Roy I. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against freeze-thawing. Int J Pharm 2011;414:140-7.
  28. Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 2007;96:547-57.
  29. Kurzatkowski W (Department of Sera and Vaccines Evaluation, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland). Personal communication.